Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5700302 | Clinical Oncology | 2006 | 9 Pages |
Abstract
Bortezomib can cause a predominately sensory axonal polyneuropathy. Pre-existing peripheral nervous system disorders, such as neuropathy and radiculopathy, are common in patients with cancer, and may pre-dispose to the development of symptomatic neuronal toxicity when treated with bortezomib. Baseline electrodiagnostic evaluation may identify patients with pre-existing peripheral nervous system disorders at risk for additive neuronal toxicity from neurotoxic chemotherapeutic agents.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.D. Stubblefield, S. Slovin, B. MacGregor-Cortelli, J. Muzzy, H. Scher, J. Wright, D. Esseltine, D. Schenkein, O.A. O'Connor,